I

Icon

Global drug and device development services

Project Manager

Full-Time
$110.5k - $138.2k+ Performance-related incentives
Mid
Bachelor's
Farmingdale, NY, USA
In PersonOffice-based with flexibility; no remote or hybrid attendance schedule is specified.
Project & Program ManagementProject Management
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • 2–3 years of experience in a laboratory or clinical research-based environment.
  • A bachelor's degree in project management, business, or a related field is preferred, with significant experience in project management and team leadership.
  • Certification in Lean Six Sigma or related process-improvement methodologies.
  • A proven track record of managing projects from inception to completion and delivering within scope, time, and budget constraints.
  • Strong leadership and organizational skills, including the ability to manage project teams and prioritize tasks.
  • Excellent communication and interpersonal skills to build relationships and manage stakeholder expectations.
  • Proficiency in project management tools and methodologies.
Responsibilities
  • Promote a culture of process improvement and ensure processes are streamlined to maximize efficiency, add business value, and meet client needs.
  • Conduct workshops with subject matter experts to map current processes, identify issues, and design streamlined processes that improve efficiency and effectiveness.
  • Support and guide the business on metrics definition and evaluation, as well as reporting tools, and contribute to data-driven decision-making.
  • Develop and manage detailed project plans, including timelines, budgets, and resource allocation, to ensure successful project delivery.
  • Lead cross-functional project teams, coordinate efforts to meet project objectives, and facilitate effective communication and collaboration.
  • Monitor project progress, identify potential risks and issues, and implement strategies to address challenges and keep projects on track.
  • Engage stakeholders to manage expectations, provide updates, and ensure alignment with project goals and organizational objectives.
  • Perform other duties as assigned by senior management.
Desired Qualifications
  • Certifications such as Project Management Professional (PMP) or PRINCE2 are advantageous.

About the company

Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Get referred to Icon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Anthropic collaboration launched July 28, 2026, giving ICON a marquee AI partnership.
  • Q2 2026 gross bookings rose 24.1% and net book-to-bill reached 1.51.
  • Backlog climbed to $23.4 billion by June 30, 2026, improving near-term demand visibility.

What critics are saying

  • ICON restates 2023-2025 revenue after Audit Committee found material weaknesses in controls.
  • 2026 revenue guidance of $7.85 billion-$8.15 billion signals decline from $8.251 billion in 2025.
  • Senior unsecured refinancing on August 13, 2026 raises fixed costs while margins already fell.

What makes Icon unique

  • ICON’s Orbis platform embeds Claude across trial planning, enrollment risk, and protocol optimization.
  • ICON’s 55-country footprint and 40,200-person delivery network support global clinical execution.
  • ICON’s $23.4 billion backlog gives sponsors unusually deep revenue visibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Paid Vacation
  • 401(k) Retirement Plan
  • Mental Health Support
  • Life Insurance
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

0%

1 year growth

31%

2 year growth

31%
International Business Times Australia
Oct 28th, 2026
ICON shares jump 13% as clinical research firm beats estimates on strong bookings and expands buyback plan.

ICON shares jump 13% as clinical research firm beats estimates on strong bookings and expands buyback plan. The contract research organisation reported $3.15 billion in net business wins, raised its buyback authorisation and forecast 2026 revenue of up to $8.2 billion. Published 10/29/26 AT 1:08 AM AEDT Shares of ICON plc rose nearly 13% on Wednesday. The clinical research company reported third-quarter earnings that beat expectations, strong new business wins and an expanded share buyback. ICON shares gained $23.22, or 12.69%, to $206.20 in early trading on the Nasdaq. The gain lifted the company's market value to about $15.9 billion. The stock is up about 10% over the past 52 weeks. Quarterly results For the third quarter, ICON reported: Revenue of $2.02 billion, down 2.9% from a year earlier Adjusted earnings of $2.66 a share, down from $3.20 a year earlier but up 3.9% from the second quarter GAAP net income of $122.1 million, or $1.58 a share, compared with a loss a year earlier Adjusted EBITDA of $336.9 million, a 16.6% margin The results beat analysts' expectations, according to market reports. The shares had jumped in premarket trading. Strong bookings Investors focused on ICON's new business. The company reported net business wins of $3.15 billion and gross bookings of $3.79 billion, up 26.9% from a year earlier. Its book-to-bill ratio, which compares new business with revenue, was 1.56. A figure above 1 means a company is adding business faster than it is completing work, which points to future revenue growth. ICON's backlog rose 4.8% from the previous quarter to $24.5 billion. Buyback expanded ICON repurchased $400 million of its shares during the quarter at an average price of $170 a share. It raised its total buyback authorization to $750 million. "We remained focused on disciplined capital allocation, returning $400 million to shareholders," Chief Executive Barry Balfe said. In August, the company issued $2.15 billion of investment-grade bonds, using the proceeds to repay debt. Updated guidance ICON updated its 2026 forecast, projecting revenue of $8.1 billion to $8.2 billion and adjusted earnings of $10.35 to $10.65 a share. "Our updated full-year financial guidance reflects sustained operational progress and higher pass-through activity," Balfe said. Pass-through revenue refers to costs ICON incurs on behalf of clients, such as payments to clinical trial sites, which it passes on to customers. Industry backdrop ICON, based in Dublin, is one of the world's largest contract research organizations. These companies run clinical trials for pharmaceutical, biotechnology and medical device companies. The industry has faced pressure over the past year as biotech funding tightened and some large drugmakers cut research budgets or reprioritized pipelines, leading to project cancellations and delays. ICON's revenue has declined as a result. The strong bookings suggest demand may be recovering. Biotech funding has improved this year, and a wave of positive clinical data across the industry, including at the European Society for Medical Oncology Congress this month, has lifted sentiment. ICON generated free cash flow of $302.4 million in the quarter. It ended September with $809 million in cash and net debt of $2.6 billion. What to watch Investors will look for evidence that the strong bookings translate into revenue growth next year, and for continued improvement in cancellation rates. They will also watch ICON's 2027 outlook, typically provided early in the new year. MEET IBT NEWS FROM BELOW CHANNELS

Defense World
Oct 2nd, 2026
Icon (NASDAQ:ICLR) stock rating upgraded by UBS Group.

Icon (NASDAQ:ICLR) stock rating upgraded by UBS Group. Icon (NASDAQ:ICLR - Get Free Report) was upgraded by analysts at UBS Group to a "hold" rating in a research report issued on Wednesday, Zacks reports. ICLR has been the subject of a number of other research reports. Royal Bank Of Canada raised shares of Icon from a "sector perform" rating to an "outperform" rating and increased their target price for the company from $126.00 to $185.00 in a research report on Thursday, June 25th. Robert W. Baird set a $194.00 price objective on shares of Icon in a research note on Friday, July 31st. Truist Financial reissued a "buy" rating and set a $209.00 target price (up from $207.00) on shares of Icon in a research note on Friday, July 31st. TD Cowen boosted their target price on shares of Icon from $164.00 to $197.00 and gave the company a "buy" rating in a report on Thursday, June 25th. Finally, Citigroup cut their price target on shares of Icon from $180.00 to $175.00 and set a "neutral" rating on the stock in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Icon presently has an average rating of "Hold" and a consensus target price of $172.40. Icon trading down 4.8%. ICLR opened at $161.85 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. Icon has a fifty-two week low of $66.57 and a fifty-two week high of $203.91. The company's 50 day moving average price is $167.35 and its two-hundred day moving average price is $144.42. The firm has a market capitalization of $12.39 billion, a price-to-earnings ratio of 37.99, a PEG ratio of 7.87 and a beta of 1.24. Icon (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping analysts' consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. Icon's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.26 earnings per share. As a group, research analysts predict that Icon will post 9.56 earnings per share for the current year. Insider activity at Icon. In related news, Director Ronan Murphy sold 5,005 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $175.00, for a total transaction of $875,875.00. Following the transaction, the director directly owned 3,847 shares of the company's stock, valued at $673,225. This represents a 56.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ciaran Murray sold 2,677 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $439,804.33. Following the transaction, the director directly owned 20,452 shares in the company, valued at approximately $3,360,059.08. This represents a 11.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 22,796 shares of company stock worth $3,887,139. Corporate insiders own 44.00% of the company's stock. Hedge funds weigh in on Icon. Several institutional investors have recently made changes to their positions in ICLR. Abound Financial LLC acquired a new stake in shares of Icon in the 4th quarter valued at about $54,000. GAMMA Investing LLC raised its stake in Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company's stock worth $68,000 after buying an additional 69 shares during the period. Global Retirement Partners LLC boosted its holdings in Icon by 308.2% in the fourth quarter. Global Retirement Partners LLC now owns 547 shares of the medical research company's stock worth $100,000 after acquiring an additional 413 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Icon by 120.0% in the second quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company's stock valued at $107,000 after acquiring an additional 336 shares during the period. Finally, Blue Trust Inc. grew its stake in Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company's stock valued at $73,000 after acquiring an additional 444 shares during the period. Institutional investors and hedge funds own 95.61% of the company's stock. About Icon. ICON plc is a global contract research and clinical development organization headquartered in Dublin, Ireland. The company provides outsourced services to pharmaceutical, biotechnology, medical device and government organizations, supporting the development and commercialization of healthcare products. Its services span clinical trial management, clinical and regulatory consulting, data management, biostatistics, medical writing, pharmacovigilance, laboratory services, medical imaging and commercialization support. Further reading. Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Yahoo Finance
Aug 28th, 2026
Icon shares up 2.5% post-earnings despite missing EPS estimates, reiterates $7.85B–$8.15B revenue guidance

Icon PLC shares rose 2.5% in the month following its latest earnings report, underperforming the S&P 500. The company posted second-quarter adjusted earnings per share of $2.56, down 21.5% year-over-year and missing analyst estimates by 0.4%. Total revenues increased 1.4% to $2.06 billion, beating consensus estimates by 3.5%. On a constant-currency basis, revenues grew 0.4%. Icon reiterated its full-year 2026 guidance, expecting revenues between $7.85 billion and $8.15 billion. Adjusted earnings per share are forecast in the range of $10.00 to $11.00. Since the earnings release, analyst estimates have trended downward. The stock currently holds a Zacks Rank of Hold, suggesting expected in-line returns in coming months.

MarketBeat
Aug 11th, 2026
Insider selling: Icon (NASDAQ:ICLR) CEO sells $62,674.74 in stock.

Insider selling: Icon (NASDAQ:ICLR) CEO sells $62,674.74 in stock. August 11, 2026 Key points. * Icon CEO Barry Edward Balfe sold 382 shares for approximately $62,675, reducing his direct holdings by 7.37%. The sale was made to cover tax withholding obligations tied to vested equity awards. * Icon reported quarterly EPS of $2.56, narrowly exceeding estimates, while revenue reached $2.06 billion and increased 2.3% year over year. * Analyst sentiment is mixed, with a consensus rating of "Hold" and an average price target of $170.40; institutional investors own 95.61% of the company. * MarketBeat previews the top five stocks to own by September 1st. Icon Plc (NASDAQ:ICLR - Get Free Report) CEO Barry Edward Balfe sold 382 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $164.07, for a total value of $62,674.74. Following the sale, the chief executive officer directly owned 4,804 shares in the company, valued at approximately $788,192.28. The trade was a 7.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Icon price performance. Icon stock traded down $0.47 during midday trading on Tuesday, reaching $165.58. 656,816 shares of the company were exchanged, compared to its average volume of 1,388,886. The firm's 50-day simple moving average is $160.91 and its 200-day simple moving average is $134.45. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The company has a market capitalization of $12.68 billion, a price-to-earnings ratio of 38.87, a P/E/G ratio of 6.82 and a beta of 1.21. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. Icon (NASDAQ:ICLR - Get Free Report) last released its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.26 EPS. On average, analysts anticipate that Icon Plc will post 9.57 EPS for the current year. Analyst ratings changes. ICLR has been the subject of several recent analyst reports. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. Truist Financial reissued a "buy" rating and set a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday, July 31st. UBS Group set a $160.00 price objective on Icon in a report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price objective on Icon from $130.00 to $155.00 and gave the company a "neutral" rating in a research report on Thursday, June 25th. Finally, William Blair upgraded Icon to a "strong-buy" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $170.40. Discover more Market cap calculator AI infrastructure stocks Mathematics Institutional investors weigh in on Icon. A number of institutional investors have recently bought and sold shares of ICLR. WINTON GROUP Ltd purchased a new position in Icon during the second quarter worth approximately $254,000. Daiwa Securities Group Inc. grew its stake in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company's stock valued at $4,094,000 after buying an additional 4,546 shares during the period. Frontier Capital Management Co. LLC grew its stake in shares of Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company's stock valued at $10,379,000 after buying an additional 35,253 shares during the period. Peapack Gladstone Financial Corp acquired a new stake in shares of Icon during the 2nd quarter worth $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company's stock worth $113,000 after buying an additional 289 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors. About Icon. Icon plc NASDAQ: ICLR is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas. Icon's service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Icon, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list. While Icon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

StreetInsider
Aug 6th, 2026
ICON prices $2.15B in senior unsecured notes to refinance debt

ICON plc has priced $2.15 billion in senior unsecured notes through its subsidiary, ICON Investments Six Designated Activity Company. The offering comprises three tranches: $500 million of 5.064% notes due 2029, $1.0 billion of 5.421% notes due 2031, and $650 million of 5.995% notes due 2036. The notes will be guaranteed by ICON on a senior unsecured basis. The offering is expected to close on 13 August 2026, subject to customary closing conditions. ICON intends to use proceeds to repay all outstanding borrowings under its bridge facility credit agreement, repay all outstanding senior secured term loans, and redeem its 5.809% Senior Secured Notes due 2027. Upon repayment, collateral securing ICON's revolving credit facility will be automatically released.